Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 2, 2014, Pages 171-174

  Cagle, Philip T ^a   Sholl, Lynette M ^b   Lindeman, Neal I ^b   Alsabeh, Randa ⁱ   Divaris, Dimitrios X G ^c   Foulis, Philip ^d   Lee, Gemma ^e   Neal, Joel W ^f   Nowak, Jan A ^g   Yu, Peter P ^h  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GRAND RIVER HOSPITAL   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Cancer Information Program   (Canada)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^h PALO ALTO MEDICAL FOUNDATION   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

CARCINOMA; EDUCATION; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MEDICAL EDUCATION; MEDICAL RECORD; MEDICAL SOCIETY; METABOLISM; METHODOLOGY; MUTATION; NOTE; PATHOLOGY; PRACTICE GUIDELINE; UNITED STATES;

CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; EDUCATION, MEDICAL, CONTINUING; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MEDICAL RECORDS; MUTATION; NEOPLASM PROTEINS; PATHOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84893670315     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0232-CP     Document Type: Note

References (16)

1. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011;9(suppl 5):S1-S32.
2. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [published online ahead of print April 4, 2013]. Arch Pathol Lab Med. doi: 10.5858/arpa. 2012-0720-OA.
3. Maemondo M, Inoue A, Kobayashi K, et al North-East Japan Study Group. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388.
4. Mitsudomi T, Morita S, Yatabe Y, et al West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11(2):121-128.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from ''never smokers'' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101(36):13306-13311.
7. Rosell R, Carcereny E, Gervais R. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
8. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
10. Paez JG, J anne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676): 1497-1500.
11. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381.
12. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
13. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):e17. doi:10.Journal.pmed.0020017.
14. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188. doi: 10.1186/1476-4598-9-188.
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-1043.
16. Cardarella S, Ortiz TM, Joshi VA, et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1767-1774.